CEO Interview: Thalia’s RNA Therapeutics Strategy

AI SummaryClose X

Thalia Therapeutics plc announced the release of a video interview with its CEO, Dr. David Solomon, detailing the company's strategic shift towards high-value RNA therapeutics and its ongoing development of Nuvec®, a proprietary gene delivery system. The interview highlights Thalia's focus on opportunities within cardiovascular disease and oncology, aiming to address unmet medical needs with its innovative RNA-based treatments and delivery platform.

Disclaimer*

UK 100

Latest directors dealings